An Open Label Single Arm Extension Study to Further Evaluate the Safety, Tolerability and Treatment Response of GBT440 in Patients With Sickle Cell Disease Who Participated in the Phase 1 Study GBT440-001
Phase of Trial: Phase II
Latest Information Update: 29 Jan 2019
At a glance
- Drugs Voxelotor (Primary)
- Indications Sickle cell anaemia
- Focus Adverse reactions
- Sponsors Global Blood Therapeutics
- 29 Jan 2019 According to a Global Blood Therapeutics media release, data from the phase 1/2 study (NCT02285088) and the open-label extension (NCT03041909) were published in the online Journal Blood, a peer-reviewed publication of the American Society of Hematology.
- 17 Jan 2019 Results of multiple doses of voxelotor in patients published in the Blood.
- 13 Feb 2018 Status changed from active, no longer recruiting to completed.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History